Nivolumab versus Everolimus in advanced renal-cell carcinoma

Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.



Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment.


A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety.

Similar Articles

Survival and prognostic stratification of 670 patients with advanced renal cell carcionma

Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.

Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma

Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.

DNA mismatch repair genes in renal cell carcinoma

Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.

Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors

Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L

Mismatch repair gene mutations in renal cell carcinoma

Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.

PD-1 blockade in tumors with mismatch-repair deficiency

Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.

Mismatch repair-deficient cancers are targets for anti-PD-1 therapy

Author(s): Kelderman S, Schumacher TN, Kvistborg P